CER Daily Newsfeed

Tarlatamab Improves Overall Survival in Extensive-Stage SCLC

(4/14, Jared Kaltwasser, The American Journal of Managed Care) reports “Tarlatamab-dlle significantly improves overall survival in SCLC compared to standard chemotherapy, as demonstrated in the phase 3 DeLLphi-304 trial.” Full

'Most-Favored Nation' Drug Pricing Has Three Significant Problems

(4/14, Darius Lakdawalla and Dana P. Goldman, STAT) comments “...For new drugs, the U.S. should establish a system that leverages the latest advances in economic methods for computing value. This system would limit U.S. prices to rational estimates of their true value to patients, but not go so far as to torpedo appropriate incentives for medical innovation. Our research has shown that shifting to a European pricing model in the U.S. would lead to shorter, less healthy lives for Americans, adding up to a loss of trillions of dollars. Uncertainty or disagreement over the effectiveness of new medicines can be addressed via outcomes-based pricing agreements, where prices rise with good performance and fall when drugs fail to fulfill their promise.” Full

How Registries and Real-World Data Are Influencing the Future of Idiopathic Pulmonary Fibrosis Care

(4/14, Ahmed Fahim, Hospital Healthcare Europe) reports “Idiopathic pulmonary fibrosis (IPF) is the most prevalent type of progressive interstitial lung disease, characterised by irreversible fibrosis and a poor long-term prognosis. Dr Ahmed Fahim discusses his work on the UK IPF Registry, which has collected real-world data on patients diagnosed with IPF, and how these findings will enhance understanding and promote advances in the clinical management of this challenging condition.” Full